Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $192.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 12.28% from the company’s previous close.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Other analysts have also recently issued reports about the stock. ValuEngine raised shares of Sartorius from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. DZ Bank reaffirmed a “sell” rating on shares of Sartorius in a research note on Wednesday, May 15th.

OTCMKTS:SARTF remained flat at $$171.00 during mid-day trading on Wednesday. 100 shares of the company traded hands, compared to its average volume of 5. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.37 and a quick ratio of 0.77. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 56.62 and a beta of -0.06. Sartorius has a 52-week low of $109.50 and a 52-week high of $175.25.

Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings data on Thursday, April 18th. The company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.16. The firm had revenue of $494.79 million for the quarter, compared to analysts’ expectations of $439.53 million. Sartorius had a net margin of 10.28% and a return on equity of 18.90%. Equities research analysts expect that Sartorius will post 3.45 earnings per share for the current fiscal year.

About Sartorius

There is no company description available for Sartorius AG.

Featured Article: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.